{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T20:25:09Z","timestamp":1792959909539,"version":"4.5.0"},"reference-count":43,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Rebecca L. Cooper Foundation","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}]},{"name":"Australian National Health and Medical Research Council","award":["NHMRC_APP1188987"],"award-info":[{"award-number":["NHMRC_APP1188987"]}]},{"name":"Luminesce Alliance","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}]},{"name":"Cystic Fibrosis Australia The David Millar Giles Innovation Grant","award":["No Grant\/Award number"],"award-info":[{"award-number":["No Grant\/Award number"]}]},{"name":"Sydney Children\u2019s Hospitals Foundation","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,11,13]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      CFTR modulators have transformed cystic fibrosis (CF) treatment, but individual responses vary even among patients with identical\n                      <jats:italic>CFTR<\/jats:italic>\n                      genotypes. This underscores the need for predictive biomarkers to optimise therapeutic selection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We evaluated 24 paediatric patients homozygous for F508del-\n                      <jats:italic>CFTR<\/jats:italic>\n                      , assessing lung function (FEV1pp) and sweat chloride (SC) before and after CFTR modulator therapy. Whole-gene sequencing was utilised to identify\n                      <jats:italic>CFTR<\/jats:italic>\n                      and pharmacogene variants. Patient-derived human nasal epithelial cells (HNECs) were expanded and differentiated at the air-liquid interface to assess CFTR function via ion transport (\u0394Isc).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Clinical responses varied widely. Twelve participants changed modulators during the study. Sequencing identified 231 additional\n                      <jats:italic>CFTR<\/jats:italic>\n                      variants and pharmacogene polymorphisms, but none correlated with response variability. However, a significant linear relationship emerged between \u0394Isc and FEV1pp improvement in patients with baseline FEV1pp&lt;90 (R\u00b2 = 0.652, p =0.001) and SC reduction (R\u00b2 = 0.535, p=0.004). Receiver operating characteristic analysis demonstrated high predictive accuracy for SC reduction (area under the curve (AUC)=0.88) and combined FEV1pp\/SC response in patients with baseline FEV1pp&lt;90 (AUC=1.00). Exploratory analysis confirmed that \u0394Isc predicts FEV1pp changes, modulated by baseline lung function and CFTR modulator type.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patient-derived differentiated HNEC cultures serve as a robust predictive tool for CFTR modulator response in paediatric CF patients. Their integration into clinical practice can enhance personalised treatment strategies, minimising ineffective therapy use and improving CF patient outcomes with precision medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223153","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:20:26Z","timestamp":1778754026000},"page":"548-559","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive capacity of paediatric nasal epithelial cells in sequential CFTR modulator therapy"],"prefix":"10.1136","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7069-6179","authenticated-orcid":false,"given":"Laura Katherine","family":"Fawcett","sequence":"first","affiliation":[{"name":"Discipline of Paediatrics and Child health, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Respiratory Medicine, Sydney Children\u2019s Hospital Randwick, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra A","family":"Chew","sequence":"additional","affiliation":[{"name":"John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia"},{"name":"School of Biomedical Sciences, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena K","family":"Schneider-Futschik","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelin M","family":"Allan","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardip R","family":"Patel","sequence":"additional","affiliation":[{"name":"John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1963-5415","authenticated-orcid":false,"given":"Adam","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Discipline of Paediatrics and Child health, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Respiratory Medicine, Sydney Children\u2019s Hospital Randwick, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafagh","family":"Waters","sequence":"additional","affiliation":[{"name":"Discipline of Paediatrics and Child health, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Respiratory Medicine, Sydney Children\u2019s Hospital Randwick, Sydney, New South Wales, Australia"},{"name":"School of Biomedical Sciences, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"key":"2026051403202047000_81.6.548.1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026051403202047000_81.6.548.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2011.10.003"},{"key":"2026051403202047000_81.6.548.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02774-2020"},{"key":"2026051403202047000_81.6.548.4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.577263","article-title":"Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis","volume":"12","author":"Hanafin","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026051403202047000_81.6.548.5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026051403202047000_81.6.548.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2026051403202047000_81.6.548.7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5694\/mja2.52527","article-title":"The equitable challenges to quality use of modulators for cystic fibrosis in Australia","volume":"222","author":"Fawcett","year":"2025","journal-title":"Med J Aust"},{"key":"2026051403202047000_81.6.548.8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1164\/rccm.201606-1286ED","article-title":"Sweat Chloride: The Critical Biomarker for Cystic Fibrosis Trials","volume":"194","author":"Sontag","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026051403202047000_81.6.548.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.03.004"},{"key":"2026051403202047000_81.6.548.10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcf.2018.12.011","article-title":"Predictive factors for lumacaftor\/ivacaftor clinical response","volume":"18","author":"Masson","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026051403202047000_81.6.548.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.01.068"},{"key":"2026051403202047000_81.6.548.12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/21556660.2021.1912352","article-title":"Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database","volume":"10","author":"Mehta","year":"2021","journal-title":"J Drug Assess"},{"key":"2026051403202047000_81.6.548.13","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1002\/ppul.23505","article-title":"Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis","volume":"51","author":"Jordan","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"2026051403202047000_81.6.548.14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/1872312812666180328105259","article-title":"Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor","volume":"12","author":"Schneider","year":"2018","journal-title":"Drug Metab Lett"},{"key":"2026051403202047000_81.6.548.15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/humu.23389","article-title":"Cis variants identified in F508del complex alleles modulate CFTR channel rescue by small molecules","volume":"39","author":"Baatallah","year":"2018","journal-title":"Hum Mutat"},{"key":"2026051403202047000_81.6.548.16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063175","article-title":"The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor\/Tezacaftor\/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs","volume":"23","author":"Sondo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026051403202047000_81.6.548.17","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jcf.2022.11.007","article-title":"Patient-derived cell models for personalized medicine approaches in cystic fibrosis","volume":"22 Suppl 1","author":"Ramalho","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026051403202047000_81.6.548.18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01429","article-title":"Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine","volume":"9","author":"Awatade","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026051403202047000_81.6.548.19","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.LSC-2021.1"},{"key":"2026051403202047000_81.6.548.20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1105787108"},{"key":"2026051403202047000_81.6.548.21","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00169.2005"},{"key":"2026051403202047000_81.6.548.22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01176"},{"key":"2026051403202047000_81.6.548.23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jcf.2004.05.026","article-title":"Transepithelial electrical measurements with the Ussing chamber","volume":"3 Suppl 2","author":"Li","year":"2004","journal-title":"J Cyst Fibros"},{"key":"2026051403202047000_81.6.548.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07504-1"},{"key":"2026051403202047000_81.6.548.25","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99385","article-title":"Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies","volume":"3","author":"Brewington","year":"2018","journal-title":"JCI Insight"},{"key":"2026051403202047000_81.6.548.26","doi-asserted-by":"crossref","first-page":"554820","DOI":"10.3389\/fped.2020.00536","article-title":"Functional Profiling of CFTR-Directed Therapeutics Using Pediatric Patient-Derived Nasal Epithelial Cell Models","volume":"8","author":"Park","year":"2020","journal-title":"Front Pediatr"},{"key":"2026051403202047000_81.6.548.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.12.019"},{"key":"2026051403202047000_81.6.548.28","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"key":"2026051403202047000_81.6.548.29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1164\/rccm.201808-1436LE","article-title":"Might Brushed Nasal Cells Be a Surrogate for CFTR Modulator Clinical Response?","volume":"199","author":"Pranke","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026051403202047000_81.6.548.30","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1513\/AnnalsATS.202001-082RL","article-title":"Correlation between Ivacaftor-induced CFTR Activation in Airway Epithelial Cells and Improved Lung Function: A Proof-of-Concept Study","volume":"17","author":"Debley","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2026051403202047000_81.6.548.31","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01855-2024","article-title":"Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis","volume":"65","author":"Ratjen","year":"2025","journal-title":"Eur Respir J"},{"key":"2026051403202047000_81.6.548.32","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ppul.23659","article-title":"In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies","volume":"52","author":"McGarry","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2026051403202047000_81.6.548.33","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.1062766","article-title":"S945L-CFTR molecular dynamics, functional characterization and tezacaftor\/ivacaftor efficacy in vivo and in vitro in matched pediatric patient-derived cell models","volume":"10","author":"Allan","year":"2022","journal-title":"Front Pediatr"},{"key":"2026051403202047000_81.6.548.34","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1148501","article-title":"Q1291H-CFTR molecular dynamics simulations and ex vivo theratyping in nasal epithelial models and clinical response to elexacaftor\/tezacaftor\/ivacaftor in a Q1291H\/F508del patient","volume":"10","author":"Allan","year":"2023","journal-title":"Front Mol Biosci"},{"key":"2026051403202047000_81.6.548.35","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"2026051403202047000_81.6.548.36","doi-asserted-by":"crossref","unstructured":"Allan KM , Wong SL , Fawcett LK , et al . Collection, Expansion, and Differentiation of Primary Human Nasal Epithelial Cell Models for Quantification of Cilia Beat Frequency. J Vis Exp 2021. doi:10.3791\/63090","DOI":"10.3791\/63090-v"},{"key":"2026051403202047000_81.6.548.37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ijms25010114","article-title":"The Effect of Complex Alleles of the CFTR Gene on the Clinical Manifestations of Cystic Fibrosis and the Effectiveness of Targeted Therapy","volume":"25","author":"Krasnova","year":"2024","journal-title":"IJMS"},{"key":"2026051403202047000_81.6.548.38","doi-asserted-by":"crossref","DOI":"10.1186\/s40246-018-0157-3","article-title":"Integrating rare genetic variants into pharmacogenetic drug response predictions","volume":"12","author":"Ingelman-Sundberg","year":"2018","journal-title":"Hum Genomics"},{"key":"2026051403202047000_81.6.548.39","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2021-0337OC"},{"key":"2026051403202047000_81.6.548.40","doi-asserted-by":"crossref","first-page":"10377","DOI":"10.3390\/ijms231810377","article-title":"Evaluation of the Complex p.[Leu467Phe;Phe508del] CFTR Allele in the Intestinal Organoids Model: Implications for Therapy","volume":"23","author":"Kondratyeva","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026051403202047000_81.6.548.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2024.02.006"},{"key":"2026051403202047000_81.6.548.42","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jcf.2019.12.008","article-title":"The influence of CFTR complex alleles on precision therapy of cystic fibrosis","volume":"19 Suppl 1","author":"Chevalier","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026051403202047000_81.6.548.43","unstructured":"Waters S . 2025. Available: https:\/\/BioRender.com\/v19c483"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:22:08Z","timestamp":1778754128000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,14]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/thorax-2025-223153"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223153","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,7]]}}}